This presentation will provide a preview of key insights from Antibodies to Watch in 2027, including a review of antibody therapeutics first approved in 2026, those currently under regulatory review, and a projection of candidates likely to enter regulatory review by the end of 2027. The talk will also feature a focused analysis of emerging trends shaping the antibody therapeutics landscape, offering a data-driven perspective on innovation and pipeline evolution.

Ig-ABDEG is a first in class, Fc silenced IgG sweeping antibody designed to achieve rapid, deep, and sustained pan subclass IgG reduction while preserving a favorable safety profile. By combining high affinity IgG capture at physiological pH with release at endosomal pH and FcRn optimized trafficking, Ig-ABDEG enables efficient lysosomal clearance of all IgG subclasses without affecting other immunoglobulins, FcRn integrity, or albumin levels. This mechanistically differentiated approach supports chronic use in IgG mediated diseases, with a first in human study currently ongoing.

Carcinoembryonic antigen adhesion molecule 5 (CEACAM5) is overexpressed in a subset of patients with colorectal carcinomas, mucinous carcinomas of the ovary and breast, and small-cell lung carcinomas, with minimal expression in normal tissue. We have developed affibody molecules that specifically target CEACAM5-overexpressing tumors and loaded them with lutetium-177. Preclinical studies in mice showed that the constructs can be used to efficiently treat CEACAM5-overexpressing pancreatic tumors with minimal side effects.

EpiBiologic’s EpiTAC bispecific antibodies are a different therapeutic approach that can degrade receptor tyrosine kinases (RTKs) independent of their form. Removal of the oncogenic RTK and associated scaffolding function is differentiated from standard blocking approaches. Tissue-selective EpiTACs can degrade EGFR, cMET, and cKIT to drive deep, and prolonged anti-tumour activity independent of form. EpiTACs have the potential to redefine monotherapy and combination therapies. EPI-326 is a novel tissue selective EGFR approach that could address the limitations of current EGFR drugs. A phase I study of EPI-326 in patients with advanced/metastatic HNSCC and mutant EGFR NSCLC is ongoing.